Swiss pharma giant Roche (ROG: SIX) has announced positive Phase I/II data on NXT007 in people with hemophilia A, supporting its progression into Phase III clinical development.
NXT007 is a next-generation investigational bispecific antibody, engineered by Chugai, which is majority-owned by the Roche Group.
Early data from the NXTAGE study suggest that NXT007 may have the potential to provide hemostatic normalization in people with hemophilia A (without factor VIII inhibitors).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze